Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | IKBKB | O14920 | 2/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966219 | 0.92 | KDM4E (0.52) | RAB9ANPC1KDM4ENR1H4IKBKB | |
| SCHEMBL966738 | 0.91 | MAPT (0.53) | RAB9ANPC1KDM4ENR1H4POLB | |
| SCHEMBL3666640 | 0.90 | NR1H4 (0.49) | RAB9ANPC1KDM4ENR1H4IKBKB | |
| SCHEMBL16436204 | 0.89 | HSD17B10 (0.53) | RAB9ANPC1KDM4ENR1H4POLB | |
| SCHEMBL3089482 | 0.86 | MAPT (0.49) | RAB9ANPC1KDM4ENR1H4IKBKB | |
| SCHEMBL15240754 | 0.86 | NR1H4 (0.48) | RAB9ANPC1KDM4ENR1H4IKBKB | |
| SCHEMBL16675215 | 0.84 | HSD17B10 (0.49) | RAB9ANPC1KDM4ENR1H4POLB | |
| SCHEMBL3724358 | 0.83 | MAPT (0.54) | RAB9ANPC1KDM4EPOLBTP53 | |
| SCHEMBL12918699 | 0.83 | LMNA (0.65) | RAB9ANPC1KDM4EPTPN1POLB | |
| SCHEMBL12948083 | 0.83 | KDM4E (0.44) | RAB9ANPC1KDM4ENR1H4IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009584-A1 | Romp-Polymerizable Electron Transport Materials Based On A Bis-Oxadiazole Moiety | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009584-A1 | Romp-Polymerizable Electron Transport Materials Based On A Bis-Oxadiazole Moiety | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009584-A1 | Romp-Polymerizable Electron Transport Materials Based On A Bis-Oxadiazole Moiety | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2234991-A1 | ROMP-POLYMERIZABLE ELECTRON TRANSPORT MATERIALS BASED ON A BIS-OXADIAZOLE MOIETY | Georgia Tech Research Corporation (US) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080797-A1 | ROMP-POLYMERIZABLE ELECTRON TRANSPORT MATERIALS BASED ON A BIS-OXADIAZOLE MOIETY | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009584-A1 | Romp-Polymerizable Electron Transport Materials Based On A Bis-Oxadiazole Moiety | SLCO1B3, SLCO4C1, SLCO2B1 | RAB9A 3795/4885NPC1 2287/4885KDM4E 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.